Berenberg Bank Reiterates “Hold” Rating for Smith & Nephew (LON:SN)

Smith & Nephew (LON:SN)‘s stock had its “hold” rating reiterated by stock analysts at Berenberg Bank in a report issued on Friday, MarketBeat.com reports. They presently have a GBX 1,300 price objective on the stock. Berenberg Bank’s target price would indicate a potential upside of 6.08% from the company’s previous close.

Several other equities research analysts also recently weighed in on the stock. Panmure Gordon reaffirmed a “hold” rating and issued a GBX 1,200 price target on shares of Smith & Nephew in a research note on Tuesday, December 9th. Citigroup boosted their price objective on Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the company a “buy” rating in a report on Friday, October 31st. Royal Bank Of Canada cut Smith & Nephew to a “sector perform” rating and cut their target price for the stock from GBX 1,700 to GBX 1,350 in a report on Wednesday, December 17th. Finally, JPMorgan Chase & Co. reissued an “overweight” rating on shares of Smith & Nephew in a research report on Friday, November 7th. Two research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, Smith & Nephew currently has an average rating of “Hold” and a consensus target price of GBX 1,381.33.

Smith & Nephew Stock Performance

LON:SN opened at GBX 1,225.50 on Friday. The company has a debt-to-equity ratio of 70.22, a quick ratio of 0.84 and a current ratio of 2.51. The company has a 50 day moving average price of GBX 1,235.01 and a two-hundred day moving average price of GBX 1,284.35. The company has a market cap of £13.43 billion, a price-to-earnings ratio of 44.12, a P/E/G ratio of 0.46 and a beta of 0.62.

Insider Buying and Selling

In other news, insider Deepak Nath sold 1,240 shares of the business’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of GBX 1,257, for a total value of £15,586.80. Insiders own 0.19% of the company’s stock.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.